Study of secukinumab for Chinese adults with moderate-to-severe HS
Treatments studied
Part of Infections, Pain, Skin clinical trials.
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and of Chinese descent.
- You have had a doctor's diagnosis of hidradenitis suppurativa (HS) for at least 6 months.
- You currently have at least 5 painful HS bumps (abscesses or inflammatory nodules) that are spread across at least two different body areas (like both armpits or armpit and groin).
- You have not taken secukinumab or any other drug that targets the IL-17 pathway before.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you use effective birth control during the study.
- You do not have a fistula (a tunnel under the skin) count of 20 or more, active inflammatory bowel disease, or other serious conditions like tuberculosis or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This study tests whether applying secukinumab as a topical cream or as a subcutaneous injection is more effective and safer for treating hidradenitis suppurativa (a skin condition causing painful lumps). It aims to find a better way to manage symptoms in people whose condition has not improved with standard treatments.
This trial tests whether combining the drug secukinumab with surgery can help people with moderate to severe hidradenitis suppurativa (HS). It looks at how well this combination works and if it is safe over a year.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
This study measures how satisfied people with moderate to severe hidradenitis suppurativa (HS) feel with their treatment after starting Cosentyx. It is for adults in Saudi Arabia who have not taken Cosentyx before and are starting it as part of their routine care.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.